-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Eiger BioPharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2012 to 2023.
- Eiger BioPharmaceuticals, Inc. Operating Income (Loss) for the quarter ending December 31, 2023 was -$12.6M, a 48.5% increase year-over-year.
- Eiger BioPharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending December 31, 2023 was -$71.8M, a 22.6% increase year-over-year.
- Eiger BioPharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$71.8M, a 22.6% increase from 2022.
- Eiger BioPharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$92.7M, a 20.5% decline from 2021.
- Eiger BioPharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$76.9M, a 23.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)